Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1831688 | 0.97 | CYP2D6 (0.42) | CYP2D6GRIN2BCYP2C9CYP3A4GSK3B | |
| SCHEMBL1833225 | 0.82 | GSK3B (0.46) | CYP2D6GSK3B | |
| SCHEMBL1835397 | 0.81 | GSK3B (0.44) | CYP2D6GSK3B | |
| SCHEMBL1828778 | 0.79 | GSK3B (0.43) | CYP2D6GSK3B | |
| SCHEMBL1975972 | 0.79 | FKBP1A (0.39) | CYP2D6GRIN2BCYP2C9CYP3A4GSK3B | |
| SCHEMBL1832420 | 0.76 | DRD2 (0.40) | CYP2D6GSK3B | |
| SCHEMBL1832035 | 0.76 | GSK3B (0.43) | CYP2D6GSK3B | |
| SCHEMBL1832809 | 0.75 | GSK3B (0.41) | CYP2D6GSK3B | |
| SCHEMBL1830898 | 0.74 | GSK3B (0.43) | CYP2D6GSK3B | |
| SCHEMBL1831443 | 0.73 | GSK3B (0.42) | CYP2D6GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144132-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| WO-2009156865-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144132-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | TYMP, DHFR, DPYD | CYP2D6 221/4885GRIN2B 1751/4885CYP2C9 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.